🇺🇸 FDA
Patent

US 11713461

Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors

granted A61PA61P19/08A61P19/10

Quick answer

US patent 11713461 (Treatment of decreased bone mineral density with zinc and ring finger 3 (ZNRF3) inhibitors) held by REGENERON PHARMACEUTICALS, INC. expires Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
REGENERON PHARMACEUTICALS, INC.
Grant date
Tue Aug 01 2023 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jul 27 2043 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
15
CPC classes
A61P, A61P19/08, A61P19/10